PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while CRVO stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
100.00%
Positive gross profit growth while CRVO is negative. John Neff would see a clear operational edge over the competitor.
-2.59%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.59%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.34%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-10.26%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.08%
Share count expansion well above CRVO's 0.02%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.08%
Diluted share count expanding well above CRVO's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-94.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
10Y OCF/share CAGR at 75-90% of CRVO's 99.90%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
68.32%
5Y OCF/share CAGR at 50-75% of CRVO's 95.83%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
41.88%
3Y OCF/share CAGR at 75-90% of CRVO's 52.03%. Bill Ackman would press for improvements in margin or overhead to catch up.
55.55%
Net income/share CAGR at 50-75% of CRVO's 99.99%. Martin Whitman might question if the firm’s product or cost base lags behind.
79.95%
5Y net income/share CAGR at 75-90% of CRVO's 96.59%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
56.07%
3Y net income/share CAGR 1.25-1.5x CRVO's 45.89%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
188.20%
10Y equity/share CAGR above 1.5x CRVO's 100.00%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-69.82%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
327.49%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.02%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.69%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.04%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-5.63%
We cut SG&A while CRVO invests at 26.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.